How one startup foretold the neuroscience renaissance after ’50 years of shitshow’

July 28, 2021

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims.

Read the source article at endpts.com
2021-07-27 11:08:52

Share This Story!